Monograph Details
|
|
Respiratory Tract
> Lung surfactants/mucolytics
|
|
INFASURF |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Lung surfactant. |
| Generic Name |
|
Calfactant (as phospholipids 35mg/mL and 0.65mg proteins/mL); susp for intratracheal administration; preservative-free. |
| Indications |
|
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants. |
| Children |
|
See literature. Give by intratracheal administration through an endotracheal tube. 3mL/kg birth weight per dose (as 2 aliquots of 1.5mL/kg each) every 12 hours for 3 doses. |
| Adults |
|
Not applicable. |
| Precautions |
|
Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully. |
| Adverse Reactions |
|
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, requirement for mechanical ventilation, reintubation, others. |
| How Supplied |
|
Single-use vials (6mL)—1 |
|
|
|
|
